Charles Schwab Investment Management Inc. Purchases 11,388 Shares of Cardlytics, Inc. (NASDAQ:CDLX)

Charles Schwab Investment Management Inc. lifted its position in Cardlytics, Inc. (NASDAQ:CDLX) by 3.0% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 390,343 shares of the company’s stock after acquiring an additional 11,388 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Cardlytics were worth $1,249,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. GSA Capital Partners LLP lifted its holdings in Cardlytics by 1,273.2% during the 3rd quarter. GSA Capital Partners LLP now owns 382,315 shares of the company’s stock worth $1,223,000 after purchasing an additional 354,474 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Cardlytics by 711.9% in the second quarter. Renaissance Technologies LLC now owns 351,035 shares of the company’s stock worth $2,882,000 after purchasing an additional 307,800 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Cardlytics in the third quarter worth about $45,000. Bank of New York Mellon Corp grew its position in shares of Cardlytics by 15.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 135,924 shares of the company’s stock worth $1,116,000 after buying an additional 18,179 shares during the last quarter. Finally, Creative Planning boosted its holdings in Cardlytics by 35.4% in the third quarter. Creative Planning now owns 29,537 shares of the company’s stock valued at $95,000 after acquiring an additional 7,721 shares in the last quarter. 68.10% of the stock is owned by hedge funds and other institutional investors.

Cardlytics Price Performance

CDLX stock opened at $3.84 on Wednesday. The company has a debt-to-equity ratio of 2.40, a quick ratio of 1.18 and a current ratio of 1.18. The company’s fifty day moving average price is $3.91 and its 200-day moving average price is $5.34. Cardlytics, Inc. has a one year low of $2.89 and a one year high of $20.52. The company has a market capitalization of $195.16 million, a PE ratio of -0.63 and a beta of 1.53.

Cardlytics (NASDAQ:CDLX) last posted its earnings results on Wednesday, November 6th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.18. Cardlytics had a negative return on equity of 110.67% and a negative net margin of 93.55%. The firm had revenue of $67.06 million during the quarter, compared to the consensus estimate of $57.77 million. During the same period in the prior year, the company earned ($0.26) EPS. The company’s quarterly revenue was down 15.1% compared to the same quarter last year. On average, equities analysts anticipate that Cardlytics, Inc. will post -1.52 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Amit Gupta sold 22,607 shares of the company’s stock in a transaction that occurred on Thursday, October 24th. The shares were sold at an average price of $3.85, for a total value of $87,036.95. Following the completion of the sale, the chief executive officer now owns 178,519 shares of the company’s stock, valued at approximately $687,298.15. This represents a 11.24 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alexis Desieno sold 25,118 shares of the firm’s stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $3.43, for a total transaction of $86,154.74. Following the completion of the sale, the chief financial officer now owns 116,481 shares in the company, valued at $399,529.83. This represents a 17.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 68,691 shares of company stock valued at $237,767. Company insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently commented on CDLX shares. Evercore ISI started coverage on Cardlytics in a research note on Friday, October 11th. They issued an “in-line” rating and a $4.00 target price for the company. Craig Hallum raised shares of Cardlytics from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, November 6th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cardlytics in a report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $6.92.

Cardlytics Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.